

Skyrizi (risankizumab-rzaa) IV Infusion Order Form

405-442-7577 💼 405-442-7223 orders@premierinfusioncenter.com	
2 Patient Information	
 Full Name:	
 Address: Weight: kg Height: cm/in 	
Allergies: □ NKDA □	,
• Treatment Status: ☐ New ☐ Continue Last Treatment Date:/	/_
 Diagnosis (ICD-10 Selection) 	
☐ K50.90 – Crohn's disease, unspecified	
☐ K50.80 – Crohn's disease of small and large intestine	
☐ K51.90 – Ulcerative colitis, unspecified	
☐ K51.01 – Ulcerative pancolitis with complications	
☐ Other: ICD-10 Code:	
• Infusion Order	
• Induction Phase:	
□ 600 mg IV at Weeks 0, 4, and 8 (Crohn's disease)	
☐ 1200 mg IV at Weeks 0, 4, and 8 (Ulcerative colitis)	
• Infusion Duration:	
☐ 600 mg over ≥60 minutes	
☐ 1200 mg over ≥120 minutes	
• Maintenance: Subcutaneous dosing to begin at Week 12 per referring provide	der
• ☐ Flush with 0.9% sodium chloride post-infusion	
• □ Observation: □ 30 minutes post-infusion	

• Line Use &	z Access			
☐ Start PIV protocol	□ Access CVC	☐ Use PICC l	Line □ Fl	ush per standard infusion
• Adverse R	eaction & Anaphyl	axis Orders		
	sion Center Protoco se fax preferred reac	-		
• Premedica	tion (Recommende	d)		
☐ Diphenhydra ☐ Cetirizine: ☐ ☐ Methylpredn ☐ Hydrocortiso	nen: □ 500 mg nmine: □ 25 mg □ 10 mg □ PO nisolone: □ 40 mg one: □ 100 mg	□ 50 mg □ □ 125 mg □ IV	l PO □ IV	7
• Laborator	y Monitoring			
☐ TB Screenin ☐ Other: Frequency: ☐ ☐ Physician of	fice will order labs o	or equivalent w	ithin 12 montl	
• Clinical Do	ocumentation Chec	klist		
	ress notes	s, intolerance, or	ab results contraindicati	☐ Medication list
• Ordering l	Provider & Demog	raphics		
Name:NPI:Contact	Licen	se #:Pho	 ne:	Fax:
• Email:	re:			//